TMCnet News
Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical StudiesNEW YORK , Sept. 10, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced today that its contract manufacturer Eurofins Amatsigroup has begun manufacturing AXIM’s patented cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC), for use in the Company’s upcoming clinical studies on cannabis as a treatment for chemotherapy related symptoms. According to the Center of Disease Control and Prevention (CDC), about 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic each year with an average cost of $100,000 per patient per year. Chemotherapy has been proven to be an effective treatment to kill cancer cells but in the process causes damage to other cells and tissues in the body. Symptoms that many chemotherapy patients experience include a weakened immune system, pain, nausea, vomiting, and diarrhea. Eurofins Amatsigroup is one of th largest independent international contract development and manufacturing organization (CDMO) in Europe that provides biopharmaceutical analysis, formulation development and manufacturing, biological research & development, among other services. The company and its highly-qualified project management team, which has cumulative experience in the field of over 30 years, creates drug development strategies in compliance with all regulatory requirements including EMA, FDA, ANSM, ANSES, FAMHP, and PMDA. In the coming months, AXIM intends to conduct a bioequivalence study between its chewing gum with dronabinol and an FDA-approved synthetic capsule. The Company plans to provide evidence that the Company’s chewing gum with dronabinol can serve as an alternative to orally ingested dronabinol for the treatment of symptoms associated with chemotherapy. AXIM plans to formulate its gum with various amounts of dronabinol, including 2.5 mg, 5 mg and 10 mg of dronabinol, for the study. “We are excited to get started on manufacturing our gum containing dronabinol and proving that our unique delivery method can provide cancer patients with quicker and more efficient relief from their chemotherapy related symptoms,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “By offering delivery through the oral mucosa, our gum allows cannabinoids to bypass the stomach and the liver and be absorbed directly into the bloodstream.” For more information about the Company and its clinical product pipeline, please visit www.aximbiotech.com. About AXIM® Biotechnologies AXIM's flagship product, MedChew® with dronabinol, is planned to undergo a bioequivalence study in the near future to fast track through FDA as an alternative delivery mechanism. For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER Public Relations Contact: Corporate Contact Info: European Address: Investor Relations Contact:
|